Regulatory

BMS secures FDA acceptance for Camzyos sNDA

Pharmaceutical Business Review

The regulator granted the application priority review for this indication, assigning a Prescription Drug User Fee Act (PDUFA) date of 30 September 2026.

Cardiovascular

Read full story

pharminent June 2, 2026 (Last updated: June 4, 2026)

Pharmaceutical Business Review

The regulator granted the application priority review for this indication, assigning a Prescription Drug User Fee Act (PDUFA) date of 30 September 2026.

Cardiovascular

Read full story

Related Stories

Biogen’s salanersen gains FDA breakthrough therapy designation for SMA

Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars

FDA taps prior knowledge to expedite cell and gene therapy development

You May Have Missed

Lilly and Novo face off at ADA 2026 as others seek to compete in obesity

Medicare Advantage in 2026: Enrollment Update and Key Trends

The next FDA commissioner must be a champion for gene therapies

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data